Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

INBXInhibrx Biosciences, IncSigning up patients

Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)

Head and Neck Squamous Cell Carcinoma (HNSCC) · HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)

0Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

No warning signs right now. That's why the score is 0.

Score over time

Stage
Phase 2/3
Patients
450 (planned)
Started
May 14, 2024
Main results expected
Dec 2029
Fully finished
May 2031
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Phase 2: Objective Response Rate by investigator (ORRinv)

    Measured over: From randomization to progressive disease (PD) or death (up to 1 year)

  • Phase 3: Progression-Free Survival by Investigator (PFSinv)

    Measured over: From randomization to PD or death (up to 4 years)

  • Phase 3: Overall Survival (OS)

    Measured over: From randomization until death from any cause (up to 4 years)

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • none

Raw record changes

  • none yet

Trial ID NCT06295731 · record last updated 2026-10-28 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT06295731) ↗